Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

9.770 +0.080 (+0.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in Upcoming June Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Pays Off 1.25% Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports First Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Completes Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
From NeoGenomics, Inc.
Via Business Wire
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum 
From Adaptive Biotechnologies
Via GlobeNewswire
NeoGenomics Announces Chief Executive Officer Succession
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
Felicia Williams Joins NeoGenomics Board of Directors
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports Third Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.